Omnipod® 5
The first wearable, tubeless, hybrid closed loop system that integrates with the leading sensor brands, is now available for your patients with type 1 diabetes (T1D) aged 2 years and older.
Simple for you
Omnipod® 5 is always adjusting so you don’t have to1
Pod shown without necessary adhesive.
- SmartAdjust™ technology is built into each Pod.
- Adjusts basal insulin delivery automatically, adapting to changing insulin needs with every new Pod.1
- Helps correct high glucose values every 5 minutes with microboluses based on current glucose levels and a 60-minute prediction.2,3
- No need to disconnect from automated insulin delivery (with 93,7% time in automated mode, in a real-world setting)4
- Improved HbA1c and time in range across age groups vs prior therapy, while time in hypoglycaemia remained low2,3
SmartAdjust™ Technology - The Algorithm Explained
Simple for them
Improved results with no more multiple daily injections, tubing or fingersticks.6
Your patients can enjoy the benefits of Omnipod 5:
- Discreet
- Tubeless
- Waterproof**
- No need for patients to disconnect
**The Pod has an IP28 rating for up to 25 feet for 60 minutes. The Omnipod 5 Controller is not waterproof.
Screen image is an example, for illustrative purposes only. Pod shown without necessary adhesive.
- Patients previously on MDI switching to Omnipod 5, have seen success achieving a time in range of 70.8% at an average target of 110mg/dL (6.1 mmol/L)5
Simple to start
Your Patients can experience it
Your patients can try the comfort and convenience of the Pod with the Pod Experience Kit, which includes a needle-free Pod that does not deliver insulin (Controller is not included)
Initiating a Patient on Omnipod 5
Help your patients get a successful start on Omnipod® 5.
Omnipod 5 Simplifies Data Management
With Glooko®, your patient can access all of their diabetes information in one easy-to-use platform and easily share it with you.
Omnipod 5 Resources for your Patients
All of the resources, all in one place. Visit our resources page for User Guides, How-to-Videos, FAQs and more.
1. In Automated Mode, SmartAdjust technology uses your total daily insulin (TDI) to set a new Adaptive Basal Rate for you.
2. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >10.0 mmol/L or >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <3.9mmol/L or <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM. Mean HbA1c in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 7.16% vs 6.78%, P<0.0001; 7.67% vs 6.99%, P<0.0001, respectively.
3. Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >10.0 mmol/L or >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <3.9 mmol/L or <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, P=0.0185. Results measured by CGM. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, P<0.05.
4. Forlenza G, et al. Diabetes Technol Ther (2024). 69,902 Omnipod 5 users with type 1 diabetes in the United States spent a median of 93.7% time in Automated Mode. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available. Device components including the Pod, CGM transmitter, and CGM sensor may be affected by strong radiation or magnetic fields. Device components must be removed (and the Pod and CGM sensor should be disposed of) before X-ray, Magnetic Resonance Imaging (MRI), or Computed Tomography (CT) scan (or any similar test or procedure). In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to X-ray, MRI, or CT, treatment can damage these components. Check with your healthcare provider on Pod removal guidelines.
5. Forlenza G, et al. Diabetes Technol Ther (2024). 6,525 Omnipod 5 users in the United States with type 1 diabetes at the Target Glucose of 110 mg/dL (6.1 mmol/L) who utilized MDI as prior therapy had a time in range of 70.8% and time below range of 0.96%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
6. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
2. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs [adults/adolescents (n= 128; aged 14-70 yrs) children (n=112; aged 6-13.9 yrs)]. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop phase. Mean time >10.0 mmol/L or >180 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%, P<0.0001, respectively. Median time <3.9mmol/L or <70 mg/dL in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.0% vs. 1.1%, P<0.0001; 1.4% vs. 1.5%, P=0.8153, respectively. Results measured by CGM. Mean HbA1c in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 7.16% vs 6.78%, P<0.0001; 7.67% vs 6.99%, P<0.0001, respectively.
3. Sherr JL, et al. Prospective trial in 80 participants with T1D aged 2 - 5.9 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time >10.0 mmol/L or >180 mg/dL in very young children (2 - 5.9yrs) as measured by CGM: ST = 39.4%, 3-mo Omnipod 5 = 29.5%, P<0.0001. Mean time <3.9 mmol/L or <70 mg/dL in very young children (2-5.9 yrs) as measured by CGM: ST = 3.41%, 3-mo Omnipod 5 = 2.13%, P=0.0185. Results measured by CGM. Mean HbA1c: ST vs. Omnipod 5 use in very young children (2 - 5.9 yrs) 7.4% vs 6.9%, P<0.05.
4. Forlenza G, et al. Diabetes Technol Ther (2024). 69,902 Omnipod 5 users with type 1 diabetes in the United States spent a median of 93.7% time in Automated Mode. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available. Device components including the Pod, CGM transmitter, and CGM sensor may be affected by strong radiation or magnetic fields. Device components must be removed (and the Pod and CGM sensor should be disposed of) before X-ray, Magnetic Resonance Imaging (MRI), or Computed Tomography (CT) scan (or any similar test or procedure). In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to X-ray, MRI, or CT, treatment can damage these components. Check with your healthcare provider on Pod removal guidelines.
5. Forlenza G, et al. Diabetes Technol Ther (2024). 6,525 Omnipod 5 users in the United States with type 1 diabetes at the Target Glucose of 110 mg/dL (6.1 mmol/L) who utilized MDI as prior therapy had a time in range of 70.8% and time below range of 0.96%. Omnipod 5 results based on users with ≥90 days CGM data, ≥75% of days with ≥220 readings available.
6. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.